

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-12 (canceled).

Claim 13 (new). An isolated polypeptide having HPR2 polypeptide activity comprising an amino acid sequence selected from the group consisting of:

- (a) SEQ ID NO:25;
- (b) an amino acid sequence of SEQ ID NO:25 that is at least 50% of the length of the amino acid sequence of SEQ ID NO:25 and that comprises amino acids 349 through 356 of SEQ ID NO:25;
- (c) an amino acid sequence sharing at least 99% amino acid identity across the entire length of the amino acid sequence of (b);
- (d) an amino acid sequence comprising both an amino acid sequence of (b) or (c), and amino acids 216 through 245 of SEQ ID NO:16;
- (e) an amino acid sequence of (b) or (c) comprising a fragment of SEQ ID NO:25 comprising an Ig-like domain amino acid sequence;
- (f) an amino acid sequence of (b) or (c) comprising a fragment of SEQ ID NO:25 comprising a cytokine receptor domain amino acid sequence;
- (g) an amino acid sequence of (b) or (c) comprising amino acids 24 through 331 of SEQ ID NO:21; and
- (h) an amino acid sequence of (c), wherein a polypeptide comprising said amino acid sequence of (c) binds to an antibody that also binds to a polypeptide comprising an amino acid sequence of any of (a)-(b).

14 (new). The polypeptide of claim 13 wherein the Ig-like domain amino acid sequence comprises amino acids 30 through 115 of SEQ ID NO:21.

15 (new). The polypeptide of claim 13 wherein the cytokine receptor domain amino acid sequence comprises amino acids 133 through 309 of SEQ ID NO:21.

16 (new). The polypeptide of claim 13 wherein the polypeptide comprises amino acids 24 through 331 of SEQ ID NO:21 and amino acids 349 through 356 of SEQ ID NO:25.

17 (new). An isolated polypeptide having HPR2 polypeptide activity comprising an amino acid sequence selected from the group consisting of:

- (a) an amino acid sequence comprising amino acids 133 through 309 of SEQ ID NO:21 and amino acids 349 through 356 of SEQ ID NO:25;
- (b) an amino acid sequence of SEQ ID NO:25 that is at least 80% of the length of the amino acid sequence of SEQ ID NO:25 and that comprises amino acids 349 through 356 of SEQ ID NO:25; and
- (c) an amino acid sequence sharing at least 99% amino acid identity across the entire length of the amino acid sequence of (a) or (b).

18 (new). The polypeptide of claim 17 further comprising amino acids 216 through 245 of SEQ ID NO:16.

19 (new). The polypeptide of claim 17 wherein the polypeptide comprises amino acids 24 through 331 of SEQ ID NO:21.

20 (new). The polypeptide of claim 17 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:25.

21 (new). A polypeptide expressed by a process comprising providing an expression vector comprising a nucleotide sequence encoding an HPR2 polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) SEQ ID NO:25;
- (b) an amino acid sequence of SEQ ID NO:25 that is at least 50% of the length of the amino acid sequence of SEQ ID NO:25 and that comprises amino acids 349 through 356 of SEQ ID NO:25;
- (c) an amino acid sequence sharing at least 99% amino acid identity across the entire length of the amino acid sequence of (b);

(d) an amino acid sequence comprising both an amino acid sequence of (b) or (c), and amino acids 216 through 245 of SEQ ID NO:16;

(e) an amino acid sequence of (b) or (c) comprising amino acids 30 through 115 of SEQ ID NO:21;

(f) an amino acid sequence of (b) or (c) comprising amino acids 133 through 309 of SEQ ID NO:21; and

(g) an amino acid sequence of (b) or (c) comprising amino acids 24 through 331 of SEQ ID NO:21;

and culturing a recombinant host cell comprising said expression vector under conditions promoting expression of said HPR2 polypeptide.

22 (new). The polypeptide of claim 21, wherein the polypeptide is produced by a method further comprising purifying the polypeptide.

23 (new). The polypeptide of claim 21 in non-glycosylated form.

24 (new). The polypeptide of claim 21, wherein the polypeptide is produced by a method comprising culturing a recombinant host cell selected from the group consisting of mammalian cells, prokaryotic cells, and yeast cells.

25 (new). The polypeptide of claim 13, wherein the polypeptide is produced by a process comprising culturing a recombinant host cell under conditions promoting expression of said polypeptide.

26 (new). The polypeptide of claim 25 in non-glycosylated form.

27 (new). The polypeptide of claim 25, wherein the polypeptide is produced by a method comprising culturing a recombinant host cell comprising an expression vector comprising a nucleic acid encoding said polypeptide.

28 (new). The polypeptide of claim 25, wherein the polypeptide is produced by a method comprising culturing a recombinant host cell selected from the group consisting of mammalian cells, prokaryotic cells, and yeast cells.